沙库巴曲缬沙坦钠联合瑞舒伐他汀治疗高血压合并HFpEF患者的疗效及对患者血清AngⅡ、NT-ProBNP、CRP水平的影响  

Efficacy of sarkubactrosovalsartan sodium combined with rosuvastatin in hypertensive patients with HFpEF and its effect on serum levels of Ang,NT-ProBNP,and CRP.

作　　者：尚华[1] 刘艳梅 金翼 SHANG Hua;LIU Yan-mei;JIN Yi(Department of Cardiology,Fuyang Hospital of Traditional Chinese Medicine,Fuyang Anhui 236025,China)

机构地区：[1]阜阳市中医医院心内科,安徽阜阳236025

出　　处：《临床和实验医学杂志》2023年第17期1825-1828,共4页Journal of Clinical and Experimental Medicine

基　　金：安徽省自然科学基金(编号:1808085MH281)。

摘　　要：目的探究沙库巴曲缬沙坦钠联合瑞舒伐他汀治疗高血压合并射血分数维持的心力衰竭(HFpEF)患者的疗效及对患者血清氨基末端脑钠肽前体(NT-proBNP)、血管紧张素(AngⅡ)及C反应蛋白(CRP)水平的影响。方法前瞻性选取2020年1月至2022年9月阜阳市中医医院收治的81例老年高血压合并HFpEF患者作为研究对象,按照随机数字表法将患者分组:对照组(n=40)和观察组(n=41)。对照组在常规治疗的基础上联合瑞舒伐他汀治疗,观察组在对照组的基础上加用沙库巴曲缬沙坦钠,两组疗程均为8周。比较两组临床治疗有效率,分析两组患者治疗前后心功能改善情况,并记录两组治疗前后血清AngⅡ、NT-ProBNP、CRP水平,于疗程结束时,统计对比两组的不良反应发生情况。结果治疗8周后,观察组的治疗有效率为97.56%,高于对照组(77.50%),差异有统计学意义(P<0.05)。治疗后,两组的左心室射血分数(LVEF)均较治疗前升高,左心室舒张末期内径(LVEDD)和左心室收缩末期内径(LVESD)均较治疗前降低,且观察组LVEF为(58.46±4.12)%,高于对照组[(53.66±3.11)%],LVEDD和LVESD分别为(36.15±1.26)、(43.13±2.19)mm,均低于对照组[(41.22±1.55)、(52.33±2.16)mm],差异均有统计学意义(P<0.05)。治疗后,两组NT-proBNP、AngⅡ、CRP水平均较治疗前降低,且观察组NT-proBNP、AngⅡ、CRP水平分别为(1277.46±13.13)pg/mL、(42.13±2.64)pg/mL、(3.22±1.09)mg/L,均低于对照组[(1477.78±18.46)pg/mL、(68.81±10.33)pg/mL、(8.55±2.21)mg/L],差异均有统计学意义(P<0.05)。疗程结束时,观察组不良反应发生率为26.83%,稍高于对照组(12.50%),但差异无统计学意义(P>0.05)。结论对高血压合并HFpEF患者采用沙库巴曲缬沙坦钠联合瑞舒伐他汀治疗,可以提高治疗有效率,改善患者的心功能,降低血清AngⅡ、NT-ProBNP、CRP水平。Objective To explore the efficacy of shacubactrosovalsartan sodium combined with rosuvastatin in patients with heart failure with preserved ejection fraction(HFpEF)with maintained ejection fraction and its effect on serum amino-terminal brain natriuretic peptide precursor(NT-proBNP),angiotensin(Ang)and C-reactive protein(CRP)levels.Methods A prospective study was conducted on 81 elderly hypertensive patients with HFpEF admitted to Fuyang Traditional Chinese Medicine Hospital from January 2020 to September 2022.The patients were randomly divided into a control group(n=40)and an observation group(n=41)according to the random number table method.The control group received combination therapy with rosuvastatin on the basis of routine treatment,while the observation group received an additional treatment of sacubarta and valsartan sodium on the basis of the control group,the treatment course of both groups was 8 weeks.The clinical treatment efficiency of the two groups was compared,the improvement of cardiac function before and after treatment was compared,and the serum levels of Ang,NT-ProBNP and CRP were recorded between the two groups.At the end of the treatment course,the adverse reactions of the two groups were counted.Results After 8 weeks of treatment,the response rate of the observation group was 97.56%,which was higher than that of the control group(77.50%),the difference was statistically significant(P<0.05).After treatment,the left ventricular ejection fraction(LVEF)of two groups were higher than those before treatment,while left ventricular end-diastolic internal diameter(LVEDD)and left ventricular end systolic diameter(LVESD)were lower than those before treatment,the LVEF of the observation group was(58.46±4.12)%,which was higher than that of the control group[(53.66±3.11)%],LVEDD and LVESD were(36.15±1.26)and(43.13±2.19)mm,respectively,which were lower than those of the control group[(41.22±1.55)and(52.33±2.16)mm],and the differences were statistically significant(P<0.05).After treatment,the levels

关 键 词：心力衰竭 高血压 血管紧张素类 C反应蛋白质 沙库巴曲缬沙坦钠 瑞舒伐他汀 氨基末端脑钠肽前体 

分 类 号：R544.1[医药卫生—心血管疾病] R541.6[医药卫生—内科学]